|
Report Date : |
28.03.2013 |
IDENTIFICATION DETAILS
|
Name : |
LEK D.D. |
|
|
|
|
Registered Office : |
Verovskova ulica 57, 1000 Ljubljana, |
|
|
|
|
Country : |
Slovenia |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
21.07.2004 |
|
|
|
|
Com. Reg. No.: |
13654200 |
|
|
|
|
Legal Form : |
Limited liability company |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations. |
|
|
|
|
No. of Employees : |
2571 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
Slovenia |
B1 |
B1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SLOVENIA - ECONOMIC
OVERVIEW
Slovenia became the first 2004 European Union entrant to adopt the euro (on 1 January 2007) and has experienced one of the most stable political and economic transitions in Central and Southeastern Europe. With the highest per capita GDP in Central Europe, Slovenia has excellent infrastructure, a well-educated work force, and a strategic location between the Balkans and Western Europe. Privatization has lagged since 2002, and the economy has one of highest levels of state control in the EU. Structural reforms to improve the business environment have allowed for somewhat greater foreign participation in Slovenia's economy and helped to lower unemployment. In March 2004, Slovenia became the first transition country to graduate from borrower status to donor partner at the World Bank. In 2007, Slovenia was invited to begin the process for joining the OECD; it became a member in 2012. Despite its economic success, foreign direct investment (FDI) in Slovenia has lagged behind the region average, and taxes remain relatively high. Furthermore, the labor market is often seen as inflexible, and legacy industries are losing sales to more competitive firms in China, India, and elsewhere. In 2009, the global recession caused the economy to contract - through falling exports and industrial production - by 8%, and unemployment to rise. Although growth resumed in 2010, it dipped into negative territory in 2012 and the unemployment rate continued to rise, exceeding 12% in 2012
|
Source
: CIA |
|
Lek d.d. |
|
Phone |
01 580 21 11 |
|
Verovskova ulica 57 |
|
Telefax |
01 568 35 17 |
|
1000 Ljubljana |
|
E-Mail |
|
|
Slovenia |
|
Web |
|
|
|
|||
|
Crefo Nr. |
9270022631 |
Registration: |
Ljubljana |
|
Statistical Nr. |
1732811 |
Registration Nr. |
13654200 |
|
Tax Nr. |
SI87916452 |
Status |
Active |
|
Business connection |
Business connection are premissible |
(21) |
|
Terms of payment |
Within agreed terms |
(21) |
Legal form
Joined stocked Company
Founded
14/08/2002 as d.o.o. - Limited liability
company (Ltd.) 21/07/2004 as Joined stocked Company
last entry
on 19.3.2013
original
with the company name Novartis Pharma d.o.o. since 10.07.2003 with the company
name Novartis Pharma Storitve d.d.,
since
30.9.2004 with the company name Lek d.d.
on 30.9.2004
incorporation of the
daughter
company LEK d.d. (company nu. 5043425,
established
already in 1946) into
parent
company Novartis Pharma Storitve d.d. and
at the same
time change of the company name from Novartis
Pharma
Storitve d.d. into Lek d.d.
the company
LEK d.d. (company nu. 5043425) was
on 7.12.2004
from the register erased
21/07/2004, Ljubljana, 13654200 Statistical
Nr.: 1732811 Tax Nr.: SI87916452
|
Crefo Nr. |
Name / Address / Status |
From |
Share |
|
Head shareholders |
|||
|
9270022638 |
NOVARTIS PHARMA AG Lichtstr. 35, Basel Switzerland |
|
100% |
|
Currency |
Value |
|
EUR |
48.402.003 |
|
Crefo Nr. |
Name / Address / Status |
Since Power of attorney |
|
Board of Directors |
||
|
9270150860 |
Board member Ales Rokavec Bratovseva ploscad 33, 1000 Ljubljana
Slovenia |
|
|
9270156093 |
Board member Bernard Patrick Donnelly IV Gradaska ulica 8A, 1000 Ljubljana Slovenia |
|
9270019046 |
Board member Bojan Dolenc Srednje Bitnje 11, 4209 Zabnica Slovenia |
|
9270038404 |
Board member Ksenija Butenko Cerne Moskriceva ulica 2a, 1000 Ljubljana
Slovenia |
|
9270135628 |
Board member Samo Ros Mladinska ulica 15, 1000 Ljubljana Slovenia |
|
9270030855 |
chairman of the board Vojmir Urlep RoZna ulica 13, 1370 Logatec Slovenia |
|
9270038397 |
Board member Zvonko Bogdanovski RoZnadolina, Cesta VI 1a, 1000 Ljubljana
Slovenia |
|
Supervisory Board |
|
|
9270038407 |
member of the supervisory board Aleksander Koren Groznikova ulica 17, 1000 Ljubljana
Slovenia |
|
9270147509 |
member of the supervisory board Cesare Frontini Baaderstrasse 1a, 80469 Miinchen Germany |
|
9270146558 |
Vice chairman of the board of directors George Jeffrey Pilgram JAKOB BUKHARDT STR. 61, 4052 BASEL USA |
|
9270038415 |
President Peter Goldschmidt Herterichstrasse 31, 81479 Miinchen Germany |
|
9270151539 |
member of the supervisory board Peter Svete Laze pri Borovnici 10A, 1353 Borovnica
Slovenia |
|
9270156094 |
member of the supervisory board Ulrich Mager Knut Elsternweg 8, 4104 Bottmingen Switzerland |
|
Valid from |
Residence address |
Valid until |
|
|
Verovskova ulica 57, 1000 Ljubljana,
Slovenia Phone: 01 580 21 11 Telefax: 01 568 35 17
E-Mail: info@lek.si Web: www.lek.si |
|
|
Crefo Nr. |
Name / Address / Status |
Valid from |
Share |
|
Owner |
|||
|
9270074063 |
NOVARTIS VETERINA d.o.o. Statistical Nr.: 2036568 Verovskova ulica 57, 1000 Ljubljana
Slovenia |
|
2.086.463 EUR |
|
9270038426 |
Hotel Lek d.o.o. Slovenia |
|
100 % |
|
9270038428 |
Novartis Veterina d.o.o. Slovenia |
|
100 % |
|
9270038430 |
Lek Zagreb d.o.o. Croatia |
|
100 % |
|
9270038431 |
Lek Skopje d.o.o. Macedonia |
|
100 % |
|
9270038432 |
Lek Ljubljana Holding GmbH Austria |
|
100 % |
|
9270038433 |
Cistilna naprava Lendava d.o.o. Slovenia |
|
74 % |
|
9270038434 |
Lek Pharmaceuticals Inc. USA |
|
100 % |
|
9270071628 |
IEDC d.o.o. Statistical Nr.: 1197843 Presernova cesta 33, 4260 Bled Slovenia |
|
158.571 EUR |
|
9270071640 |
TEHNOLOSKI PARK LJUBLJANA d.o.o. Statistical Nr.: 5911508 Tehnoloski park 19, 1000 Ljubljana Slovenia |
|
10.606,59 EUR |
|
Head shareholders |
|||
|
9270038429 |
Sandoz d.d. Statistical Nr.: 2159287 Verovskova ulica 57, 1000 Ljubljana
Slovenia |
|
100 % |
|
Main activity |
Nace |
|
Manufacture of pharmaceutical preparations |
21.20 |
Additional activities Nace
company
activity:
manufacture of pharmaceutical preparations, chemicals,
cosmetics, dental products, research and development, quality control, advisory
engineering, tourism, export-import representation and mediation
(all this activities are within the company
since september 2004 after the incorporation of the company Lek d.d., before
the activity was only managing of the companies)
headquarters and the part of the manufacture
premises are located on the address above branc offices are located:
in Menges, Kolodvorska cesta 27 (manufacture
of raw materials for the company use and for further sale), - in Lendava,
Trimlini 2D, (manufacture of cosmetics, manufacture of
pharmaceutical raw materials) - in Lipovci,
Lipovci 251D, Beltinci (veterinary programme) - in Prevalje, Perzonali 47
(dental programme) - Ljubljana, Celovska cesta 135 (research and development)
the company has wide sales net and a great
deal of
licence partners who transfered their sales
rights for
their products on the company, for example:
Meck and Co.
(USA), Farmitalia (Italy), E.Merck (Germany),
Ivoclar/Vivadent (Lichtenstein), Revlon (USA)
etc.
selling structure: 77\/ Central-and
Easteurope, 10\/ Asia and
Latin Amerika,
9\% Slovenia, 2\% Afrika,Australia, 2\%
Westeuropa, USA, Canada
Economic data
Turnover and Employees
|
Date |
Turnover |
Employees |
|
2007 |
772.499.801 EUR |
2456 |
|
2008 |
729.193.527 EUR |
2500 |
|
2009 |
581.597.375 EUR |
2435 |
|
2010 |
575.865.113 EUR |
2472 |
|
2011 |
645.328.141 EUR |
2500 |
|
2012 |
|
2571 |
|
group Lek |
|
|
|
|
Annual |
turnover |
2011 |
EUR
773.551.330,-- |
|
Profit |
2011 |
EUR |
79.654.660,-- |
|
Annual |
turnover |
2010 |
EUR
734.517.330,-- |
|
Profit |
2010 EUR |
67.003.820,-- |
|
|
Annual |
turnover |
2009 |
EUR
731.591.573,-- |
|
Profit |
2009 |
EUR |
48.747.940,-- |
|
Annual |
turnover |
2008 |
EUR
831.502.677,-- |
|
Profit |
2008 |
EUR |
97.989.770,-- |
Annual
turnover 2007 Profit 2007 EUR
EUR
973.760.702,--81.200.979,--
Import / Export
|
|
Import |
Export |
|
Percentage |
Unknown |
Unknown |
|
Countries |
India, Germany, Spain, Japan, USA, China,
Italy, Switzerland, Austria |
Unknown |
Properties
|
Name |
Detail |
Currency |
Value |
|
Land and buildings |
Company's property per 31.12.2011 |
EUR |
99.683.935 |
Remarks
company name:
LEK farmacevtska druzba d.d.firma v angleskem
jeziku: Lek Pharmaceuticals d.d.firma v
franc.j:Societe Pharmaceutique Lek d.d.
participation in capital:
Hotel Lek d.o.o. Kranjska Gora(100% share)
Sandoz d.d.Ljubljana(100% share)
CN Lendava d.o.o. (74,5% share)
Novartis Veterina d.o.o. Ljubljana (100%
share)
Lek Ljubljana Holding GmbH Austria(100%
share)
Lek Skopje d.o.o.Macedonia(100% share)
Lek Pharmaceuticals, Inc. USA (100% share)
(stand per 31.12.2011)
Representations are located in BiH,
Georgien, Ukraine, Kasachstan, Poland,
Russia, Usbekistan, Belaruss
|
Code |
Bank name / Address |
Account Nr. |
|
122 |
ABANKA VIPAd.d. Slovenska cesta 58, 1517 Ljubljana , 1517, |
05100-8000005424 |
|
124 |
RAIFFEISEN BANKA d.d. Slovenska ulica 17, 2000 Maribor , 2000, |
SI56 242039062678839 |
Payment experience
Balance
31.12.2011 The enclosed balance of 2011 is originated from official source, it is
authenticated by the auditor. 31.12.2010 The enclosed balance of 2010 is originated from official source, it is
authenticated by the auditor. 31.12.2009 The enclosed balance of 2009 is originated from official source, it is
authenticated by the auditor. 31.12.2008 The enclosed balance of 2008 is originated from official source, it is
authenticated by the auditor.
|
|
|
31/12/2011 1 EUR balance |
31/12/2010 1 EUR balance |
31/12/2009 1 EUR balance |
31/12/2008 1 EUR balance |
|
Name |
Ref. |
||||
|
ASSETS (AKTIVA) |
|
873.377.827 |
829.067.311 |
897.595.525 |
1.120.673.184 |
|
LONG-TERM ASSETS |
|
579.329.027 |
557.910.920 |
586.739.453 |
594.534.417 |
|
Intangible assets and long-term deferred
costs and accrued revenues |
|
341.658.420 |
341.924.167 |
342.328.717 |
342.681.153 |
|
Intangible assets |
|
341.685.420 |
341.896.682 |
342.328.717 |
|
|
Long-term deferred costs and accrued
revenues |
|
0 |
27.485 |
0 |
|
|
Tangible fixed assets |
|
227.756.959 |
206.449.360 |
225.935.390 |
232.731.041 |
|
Long-term financial investments and Real
estate investments |
|
9.837.393 |
9.537.393 |
18.474.130 |
18.474.648 |
|
Investment property |
|
0 |
0 |
0 |
|
|
Long-term financial investments |
|
9.837.393 |
9.537.393 |
18.474.130 |
|
|
Long-term operating receivables |
|
49.255 |
0 |
1.216 |
4.767 |
|
Deferred receivables for taxes |
|
0 |
0 |
0 |
642.808 |
|
SHORT-TERM ASSETS |
|
293.615.054 |
267.726.728 |
308.950.849 |
523.807.342 |
|
Short-term assets (without Short-term deferred
costs and accrued revenues) |
|
|
|
518.812.328 |
|
|
Assets (group for estrange) for sell |
|
0 |
0 |
0 |
0 |
|
Inventories |
|
112.371.786 |
101.675.463 |
117.485.131 |
140.514.398 |
|
Short-term financial investments |
|
60.610.715 |
77.582.565 |
17.785.028 |
4.995.014 |
Profit and loss accounts
31.12.2011 The enclosed profit and loss account of 2011 is originated from
official source, it is authenticated by the auditor. 31.12.2010 The enclosed profit
and loss account of 2010 is originated from official source, it is
authenticated by the auditor. 31.12.2009 The enclosed profit and loss account of 2009 is originated from
official source, it is authenticated by the auditor. 31.12.2008 The enclosed profit
and loss account of 2008 is originated from official source, it is
authenticated by the auditor.
|
|
|
31/12/2011 1 EUR balance |
31/12/2010 1 EUR balance |
31/12/2009 1 EUR balance |
31/12/2008 1 EUR balance |
|
Name |
Ref. |
||||
|
Short-term operating receivables |
|
117.730.840 |
88.317.283 |
172.696.267 |
376.576.035 |
|
Cash assets |
|
2.901.713 |
151.417 |
984.423 |
1.721.895 |
|
Short-term deferred costs and accrued revenues |
|
433.746 |
3.429.663 |
1.905.223 |
2.331.425 |
|
Off-balance sheet items |
|
0 |
6.523.939 |
10.307.379 |
|
|
LIABILITIES |
|
873.377.827 |
829.067.311 |
897.595.525 |
1.120.673.184 |
|
Long-term sources (PASSIVA) |
|
|
|
732.047.288 |
|
|
CAPITAL |
|
499.520.850 |
675.660.658 |
707.751.768 |
701.504.759 |
|
Called-up capital |
|
48.402.003 |
48.402.003 |
48.402.003 |
|
|
Basic (subscribed) capital |
|
48.402.003 |
48.402.003 |
48.402.003 |
48.402.003 |
|
Non called-up capital (deductive item) |
|
0 |
0 |
0 |
|
|
Capital reserves |
|
375.595.036 |
575.595.036 |
575.595.036 |
575.595.036 |
|
Reserves from profit |
|
0 |
0 |
0 |
|
|
Surplus from revaluation |
|
0 |
0 |
0 |
|
|
Retained net |
|
1.663.619 |
3.754.729 |
28.453.018 |
10.078.106 |
|
Net business result for the business year |
|
73.860.192 |
47.908.890 |
55.301.711 |
67.429.614 |
|
PROVISIONS AND LONG-TERM ACCRUED COSTS AND
DEFERRED REVENUES |
|
31.103.312 |
31.288.969 |
30.053.561 |
30.447.967 |
|
FINANCIAL AND BUSINESS LIABILITIES |
|
332.816.835 |
108.829.120 |
145.407.313 |
344.705.491 |
|
LONG-TERM LIABILITIES |
|
7.258.460 |
7.446.508 |
7.664.308 |
30.542.529 |
|
Provisions and long-term accrued costs and
deferred revenues |
|
|
|
30.447.967 |
|
|
Long-term liabilities |
|
|
|
94.562 |
|
|
Long-term financial liabilities |
|
0 |
0 |
0 |
0 |
|
Long-term operating liabilities |
|
0 |
0 |
0 |
94.562 |
|
Deferred liabilities for taxes |
|
7.258.460 |
7.446.508 |
7.664.308 |
|
|
Short-term liabilities and accruals |
|
|
|
388.625.896 |
|
|
SHORT-TERM LIABILITIES |
|
325.558.375 |
101.382.612 |
137.743.005 |
344.610.929 |
|
Liabilities, included in groups for
estrange |
|
0 |
0 |
0 |
|
|
Short-term financial liabilities |
|
21.385.529 |
13.229.506 |
58.850.943 |
268.119.385 |
|
Short-term operating liabilities |
|
304.172.846 |
88.153.106 |
78.892.062 |
76.491.544 |
|
SHORT-TERM ACCRUED COSTS AND DEFERRED
REVENUES |
|
9.936.830 |
13.288.564 |
14.382.883 |
44.014.967 |
|
|
|
31/12/2011 1 EUR profit and loss account |
31/12/2010 1 EUR profit and loss account |
31/12/2009 1 EUR profit and loss account |
31/12/2008 1 EUR profit and loss account |
|
Name |
Ref. |
||||
|
TOTAL REVENUES |
|
|
|
729.193.527 |
|
|
TOTAL EXPENSES |
|
|
|
647.450.540 |
|
|
Net sales |
|
623.084.466 |
552.515.632 |
561.687.358 |
|
|
Changes in the value of inventories of products
and work-in-process |
|
-5.243.600 |
-16.157.290 |
|
|
|
Capitalised own products and own services |
|
0 |
0 |
|
|
|
Other operating revenues (with subventions,
grants,... ) |
|
20.376.458 |
16.859.693 |
|
|
|
GROSS OPERATING YIELD |
|
567.648.490 |
562.389.761 |
|
|
|
Cost of goods, material and services |
|
341.427.559 |
312.926.272 |
218.110.121 |
|
|
Purchase value of goods and materials sold
and cost of material and cost of material used |
|
234.999.001 |
214.678.293 |
|
|
|
Cost of services |
|
106.428.558 |
98.247.979 |
213.055.699 |
|
|
Labour cost |
|
122.310.407 |
122.544.720 |
125.095.179 |
|
|
thereof wages |
|
|
|
89.565.176 |
|
|
Cost of wages |
|
88.594.904 |
85.345.680 |
|
|
|
Cost of pension insurance |
|
12.204.350 |
11.663.338 |
|
|
|
Cost of other social insurance |
|
6.673.066 |
6.515.984 |
|
|
|
Other labour cost |
|
14.838.087 |
19.019.718 |
|
|
|
Write-offs |
|
47.607.464 |
51.465.285 |
|
|
|
Depreciation |
|
46.607.426 |
50.806.079 |
55.803.966 |
|
|
Revaluation operating expenses for
non-tangible assets and tangible fixed assets |
|
318.338 |
494.920 |
|
|
|
Revaluation operating expenses for current
assets |
|
681.700 |
164.286 |
|
|
|
Other operating expenses |
|
2.535.508 |
1.898.229 |
2.246.144 |
|
|
write-off of working means (revaluation
expenses) |
|
|
|
399.359 |
|
|
OPERATING REVENUES |
|
572.892.090 |
578.547.051 |
700.951.673 |
|
|
Financial Revenues from salles of goods,
services and materials |
|
|
|
684.066.202 |
|
|
OPERATING EXPENSES |
|
513.880.938 |
488.834.506 |
614.710.468 |
|
|
OPERATING RESULT |
|
59.011.152 |
89.712.545 |
|
|
|
EBIT |
|
79.915.688 |
53.767.552 |
73.555.255 |
|
|
Financial income from investments in other
enterprises |
|
6.550.476 |
922.626 |
61.137 |
8.006.889 |
|
Financial income from loans |
|
1.288.149 |
462.769 |
774.109 |
|
|
Financial income from operating receivables |
|
4.621.707 |
6.617.210 |
18.291.581 |
|
|
Financial expenses from depreciation and
writeoffs of financial investments |
|
0 |
0 |
1.676 |
0 |
|
Financial expenses from financial
liabilities |
|
524.982 |
449.279 |
6.990.167 |
|
|
Financial expenses from operating
liabilities |
|
3.637.753 |
4.747.164 |
18.223.006 |
|
|
Financial income |
|
12.460.332 |
8.002.605 |
19.126.827 |
26.453.361 |
|
Financial expenses |
|
4.162.735 |
5.196.443 |
25.214.849 |
32.561.726 |
|
Other revenues |
|
1.887 |
214.018 |
80.787 |
1.788.493 |
|
|
|
31/12/2011 1 EUR profit and loss account |
31/12/2010 1 EUR profit and loss account |
31/12/2009 1 EUR profit and loss account |
31/12/2008 1 EUR profit and loss account |
|
Name |
Ref. |
||||
|
Other expenses |
|
139.941 |
1.023.711 |
596.365 |
178.346 |
|
Total revenues |
|
645.328.141 |
575.865.113 |
581.597.375 |
|
|
Total costs |
|
557.252.910 |
520.101.092 |
514.645.720 |
|
|
Total business result |
|
88.075.231 |
55.764.021 |
66.951.655 |
|
|
Tax on profit |
|
14.403.087 |
8.072.931 |
11.865.034 |
|
|
Deferred taxs |
|
-188.048 |
-217.800 |
-215.090 |
|
|
Net business result for the accounting
period |
|
73.860.192 |
47.908.890 |
55.301.711 |
|
|
Write-offs of equity and other financial
investments |
|
|
|
|
32.561.726 |
|
EARNINGS BEFORE TAXES (EBT) |
|
|
|
|
81.742.987 |
|
INCOME TAX |
|
|
|
|
14.313.373 |
|
NET EARNINGS (E) |
|
|
|
|
67.429.614 |
Financial Ratios
|
Name |
Ref. |
31/12/2011 |
31/12/2010 |
31/12/2009 |
31/12/2008 |
|
Equity ratio |
1 |
0,06 |
0,06 |
0,05 |
0,04 |
|
Cleared equity ratio |
2 |
0,06 |
0,06 |
0,05 |
0,04 |
|
Current liquidity |
3 |
0,90 |
2,64 |
2,24 |
1,52 |
|
Quick liquidity |
4 |
0,56 |
1,64 |
1,39 |
1,11 |
|
Working capital |
5 |
-31943321,00 |
166344116,00 |
171207844,00 |
179196413,00 |
|
Gearing |
6 |
18,04 |
17,13 |
18,54 |
23,15 |
|
Cleared gearing |
7 |
0,44 |
0,27 |
1,22 |
5,54 |
|
Profitability |
8 |
13,65 |
9,68 |
11,51 |
11,21 |
|
Operating profitability |
9 |
11,45 |
8,32 |
9,51 |
9,25 |
|
Stock days |
10 |
63,56 |
64,44 |
73,73 |
70,33 |
|
Debtor days |
11 |
66,59 |
55,98 |
108,38 |
188,50 |
|
Supplier days |
12 |
172,04 |
55,87 |
49,51 |
38,29 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.27 |
|
|
1 |
Rs.82.49 |
|
Euro |
1 |
Rs.69.88 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.